Volt-Age, Concordia research program and Volatus Aerospace join forces to advance energy technologies for uncrewed aircraft systems

Volatus Aerospace (VOH) stock rose to C$0.55 after announcing a US$10.5 million deal to acquire AISPECO UAB, a Lithuania-based sensor systems developer. The acquisition includes US$3.0 million in cash and US$7.5 million in shares, with a potential US$2.5 million earn-out. The company expects the deal to add C$10 million in revenue by 2027, with an 8%–12% Adjusted EBITDA margin. Analysts maintain a 'Strong Buy' rating with price targets above current levels. The stock later traded flat.

Volatus Aerospace (TSX: FLT) gained 8.62% after securing a 5-year contract from the Canadian government for 100 tactical ISR uncrewed aircraft systems, with options for 4,900 more. The deal, valued up to C$25M, includes end-to-end solutions and supports Canada's defense needs. Delivery begins in Q4 2026.

Volatus Aerospace (TSX: FLT) won a 5-year Canadian contract for up to 5,000 tactical ISR uncrewed aircraft systems, with initial 100 systems valued at max C$500,000. Delivery begins Q4 2026. The contract includes end-to-end solutions and positions Volatus for future defense opportunities.

Volatus Aerospace (TSX: FLT, OTCQX: TAKOF) said Transport Canada granted it a Letter of Acceptance under the new Pre-Validated Declaration process for its Canary remotely piloted aircraft system. The approval covers its proposed means of compliance for BVLOS operations in populated areas using onboard detect-and-avoid, enabling next verification steps and a Safety Assurance Declaration.

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.